New plasminogen activators: a clinical review. (Q33542948)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10084057%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

review article

1 reference

title

New plasminogen activators: a clinical review (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10084057%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

1 reference

A M Ross

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10084057%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

publication date

1 March 1999

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10084057%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

number of pages

7

1 reference

inferred from page(s)

published in

Clinical Cardiology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10084057%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

volume

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10084057%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10084057%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

page(s)

165-171

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10084057%20AND%20SRC:MED&resulttype=core&format=json

Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. GUSTO-I Investigators

12 November 2019

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1002%2FCLC.4960220303

Toward a new frontier in myocardial reperfusion therapy: emerging platelet preeminence

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1002%2FCLC.4960220303

A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction. The STAR Trial Group.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1002%2FCLC.4960220303

Vampire bat salivary plasminogen activator promotes rapid and sustained reperfusion without concomitant systemic plasminogen activation in a canine model of arterial thrombosis

21 January 2018

1 reference

12 December 2020

Improved thrombolysis in acute myocardial infarction with front-loaded administration of alteplase: results of the rt-PA-APSAC patency study (TAPS)

1 reference

12 December 2020

Effective thrombolysis without marked plasminemia after bolus intravenous administration of vampire bat salivary plasminogen activator in rabbits

1 reference

12 December 2020

Conjugation to antifibrin Fab' enhances fibrinolytic potency of single-chain urokinase plasminogen activator

1 reference

12 December 2020

Randomised double-blind trial of recombinant pro-urokinase against streptokinase in acute myocardial infarction. PRIMI Trial Study Group

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of saruplase, an unglycosylated single-chain urokinase-type plasminogen activator, in patients with acute myocardial infarction

1 reference

12 December 2020

Thrombolysis with recombinant unglycosylated single-chain urokinase-type plasminogen activator (saruplase) in acute myocardial infarction: influence of heparin on early patency rate (LIMITS study). Liquemin in Myocardial Infarction During Thrombolys

1 reference

12 December 2020

More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. RAPID Investigators

1 reference

12 December 2020

[Pro-urokinase for infarct therapy].

1 reference

12 December 2020

Comparison of the bleeding potential of vampire bat salivary plasminogen activator versus tissue plasminogen activator in an experimental rabbit model

1 reference

12 December 2020

Future directions in thrombolysis for myocardial infarction: what are the unanswered questions?

1 reference

12 December 2020

A faster-acting and more potent form of tissue plasminogen activator

1 reference

12 December 2020

An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators

1 reference

12 December 2020

The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction

1 reference

12 December 2020

TIMI frame count: a quantitative method of assessing coronary artery flow

1 reference

12 December 2020

Recombinant staphylokinase variants with altered immunoreactivity. II: Thrombolytic properties and antibody induction

1 reference

12 December 2020

Thrombolytic therapy in acute myocardial infarction

1 reference

12 December 2020

The promise of new genetically engineered plasminogen activators

1 reference

12 December 2020

Clinical studies with the new glycosylated recombinant prourokinase

1 reference

12 December 2020

Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction.

1 reference

12 December 2020

Thrombolytic agents--an overview.

1 reference

12 December 2020

Biochemical and pharmacologic comparison of thrombolytic agents

1 reference

12 December 2020

Fibrin-selective thrombolytic therapy with recombinant staphylokinase

1 reference

12 December 2020

Molecular biology of plasminogen activators: what are the clinical implications of drug design?

1 reference

12 December 2020

TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial

1 reference

12 December 2020

Recombinant staphylokinase variants with altered immunoreactivity. IV: Identification of variants with reduced antibody induction but intact potency

1 reference

12 December 2020

Comparison of saruplase and alteplase in acute myocardial infarction. SESAM Study Group. The Study in Europe with Saruplase and Alteplase in Myocardial Infarction

1 reference

12 December 2020

1 reference

12 December 2020

A comparison of reteplase with alteplase for acute myocardial infarction

1 reference

12 December 2020

Staphylokinase: a potent, uniquely fibrin-selective thrombolytic agent

1 reference

12 December 2020

Randomized, double-blind study comparing saruplase with streptokinase therapy in acute myocardial infarction: the COMPASS Equivalence Trial. Comparison Trial of Saruplase and Streptokinase (COMASS) Investigators

1 reference

12 December 2020

Thrombolytic therapy and equivalence trials

1 reference

12 December 2020

Extended mortality benefit of early postinfarction reperfusion. GUSTO-I Angiographic Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries Trial

1 reference

12 December 2020

Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment. GUSTO-III Investigators. Global Use of Strategies to Open Occluded Coronary Arteries

1 reference

12 December 2020

Clinical predictors of early infarct-related artery patency following thrombolytic therapy: importance of body weight, smoking history, infarct-related artery and choice of thrombolytic regimen: the GUSTO-I experience. Global Utilization of Streptok

1 reference

12 December 2020

Identifiers

DOI

10.1002/CLC.4960220303

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10084057%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10084057%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

PubMed publication ID

10084057

1 reference